ERBB2 and breast cancer: Changes in hormone levels are the underlying cause of the risk of disease and decreased serum luteinizing hormone and follicle-stimulating hormone levels after menopause are associated with increased ER and PR expression and decreased HER2 expression in breast cancer patients [44, 45].